论文部分内容阅读
目的探讨普米克令舒吸入与静脉注射甲基泼尼松龙治疗COPD急性发作的临床效果及对患者生活质量的影响。方法选择COPD急性发作患者100例,随机分为观察组与对照组各50例,其中对照组给予甲基泼尼松龙静脉注射治疗,观察组给予普米克令舒吸入治疗,比较2组临床效果、治疗前后血气指标、生活质量量表(SF-36)评分及不良反应发生率。结果观察组治疗后有效率为94.0%明显高于对照组的80.0%(χ~2=7.223,P<0.05);观察组治疗后PaCO_2、PaO_2、SaO_2、pH改善优于对照组(t1=12.381,t2=10.326,t3=11.285,t4=10.725,均P<0.05);治疗后观察组SF-36各维度评分较对照组均改善明显(P<0.05);观察组不良反应发生率为4.0%,明显低于对照组的16.0%(χ~2=8.455,P<0.05)。结论普米克令舒吸入较静脉注射甲基泼尼松龙治疗COPD急性发作疗效显著,可有效改善患者生活质量,值得临床推广应用。
Objective To investigate the clinical efficacy of pulmicort respules and intravenous methylprednisolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) and its impact on the quality of life of patients. Methods One hundred patients with acute exacerbation of COPD were randomly divided into observation group and control group, with 50 cases in each group. The control group was given methylprednisolone intravenously and the observation group was treated with pulmicort respiration. The clinical effects of two groups were compared , Blood gas index before and after treatment, quality of life scale (SF-36) score and incidence of adverse reactions. Results After treatment, the effective rate of observation group was 94.0%, which was significantly higher than that of control group (χ ~ 2 = 7.223, P <0.05); PaCO_2, PaO_2, SaO_2 and pH in observation group were better than those in control group , t 2 = 10.326, t 3 = 11.285, t 4 = 10.725, all P 0.05). After treatment, SF-36 scores in each group were significantly improved compared with the control group (P 0. 05). The incidence of adverse reactions in the observation group was 4.0% , Significantly lower than 16.0% of the control group (χ ~ 2 = 8.455, P <0.05). Conclusions Pulmicort respiration is more effective than venous injection of methylprednisolone in the treatment of acute exacerbation of COPD, which can effectively improve the quality of life of patients and is worthy of clinical application.